The overall goals in the management of heart failure are to prevent or eliminate symptoms, improve quality of life, and prolong survival. Paradoxically, as has been demonstrated with positive inotropic agents such as vesnarinone and flosequinan, chronic heart failure therapy may improve quality of life and reduce symptoms while increasing mortality. As discussed in Chapter 11, several large randomized controlled trials have demonstrated the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists on exercise tolerance, clinical signs and symptoms, neurohormonal stimulation, quality of life, and survival in patients with chronic heart failure.
KeywordsHeart Failure Left Ventricular Ejection Fraction Chronic Heart Failure Cardiac Index Severe Heart Failure
Unable to display preview. Download preview PDF.
- 4.Hjalmarson A, Waagstein F: Use of beta-blockers in the treatment of dilated cardiomyopathy. In Heart Failure: Basic Science and Clinical Aspects. Edited by Gwathmey JK, Briggs GM, Allen PD. New York: Marcel Dekker; 1993: 223–251.Google Scholar
- 17.The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357: 1385–1390.Google Scholar
- 20.Shekelle PG, Rich MW, Morton SC, et al.: Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cordial 2003, 41:1529–1538.CrossRefGoogle Scholar
- 23.Metra M, Nodari S, D’Aloia A, et al.: Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Call Cordial 2002, 40:1248–1258.CrossRefGoogle Scholar
- 26.Gattis WA, O’Connor CM, Gallup DS, et al.: Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) Trial. J Am Call Cordial 2004, 43:1534–1541.CrossRefGoogle Scholar